Vanguard Capital Management filed a Schedule 13G with the SEC on October 30, 2026, disclosing beneficial ownership of 10,999,044 shares of Revolution Medicines Inc common stock as of September 30, 2026.

Key Highlights

  • Total beneficial ownership: Vanguard Capital Management reported aggregate beneficial ownership of 10,999,044 shares of Revolution Medicines Inc common stock.
  • Percent of class: The reported stake represents 5.13% of the class, according to the filing.
  • Sole voting power: Vanguard Capital Management reported sole voting power over 1,849,510 shares, with shared voting power of 0.
  • Sole dispositive power: The filing reported sole dispositive power over all 10,999,044 shares, with shared dispositive power of 0.
  • Triggering date: The event requiring the filing occurred on September 30, 2026.
  • Affiliates included: The filing covers securities deemed beneficially owned by Vanguard Capital Management LLC and affiliates including Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC, and Vanguard Investments Australia Ltd.

Vanguard Capital Management's Schedule 13G Filing for Revolution Medicines

Vanguard Capital Management, a Pennsylvania-based investment adviser, filed a Schedule 13G disclosing its beneficial ownership position in Revolution Medicines Inc (NASDAQ:RVMD), whose principal executive offices are located at 700 Saginaw Drive, Redwood City, CA 94063. The filing was submitted on October 30, 2026, reflecting ownership as of the event date of September 30, 2026. The CUSIP number for the covered security is 76155X100.

According to the filing, the aggregate amount beneficially owned by Vanguard Capital Management is 10,999,044 shares, representing 5.13% of the class. Of those shares, the firm reported sole voting power over 1,849,510 shares and sole dispositive power over the full 10,999,044 shares. Shared voting and shared dispositive power were each reported as 0. The filing notes that Vanguard Capital Management, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, "have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein," and that "no one other person's interest in the securities reported herein is more than 5%."

The filing further states, in accordance with SEC Release No. 34-39538 (January 12, 1998), that the Schedule 13G reflects securities beneficially owned or deemed to be beneficially owned by Vanguard Capital Management LLC and affiliated entities or business divisions, including Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC, and Vanguard Investments Australia Ltd. The filing was signed by My Trieu-Gatt, identified as Authorized Signatory and Head of Global Fund Administration, on October 30, 2026.

What Was Disclosed

Vanguard Capital Management reported beneficial ownership of 10,999,044 shares of Revolution Medicines Inc common stock, equal to 5.13% of the class, with a triggering event date of September 30, 2026, and sole dispositive power over all reported shares.